Diabetologia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
Язык: Английский
Diabetologia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
Язык: Английский
Pharmaceutics, Год журнала: 2024, Номер 16(12), С. 1521 - 1521
Опубликована: Ноя. 26, 2024
Lipid nanoparticles (LNPs) have shown promise as a delivery system for nucleic acid-based therapeutics, including DNA, siRNA, and mRNA vaccines. The immune plays critical role in the response to these nanocarriers, with innate cells initiating an early adaptive mediating more specific reaction, sometimes leading potential adverse effects. Recent studies that LNPs is mediated by Toll-like receptors (TLRs) other pattern recognition (PRRs), which recognize lipid components of nanoparticles. This can trigger activation inflammatory pathways production cytokines chemokines, effects such fever, inflammation, pain at injection site. On hand, appears be primarily directed against protein encoded cargo, little evidence ongoing LNP itself. Understanding relationship between development safe effective systems. In fact, targeting essential develop vaccines, well therapies cancer or infections. There lack research literature has systematically studied factors influence interaction further needed better elucidate mechanisms underlying LNPs. this review, we discuss LNPs’ composition, physico-chemical properties, size, shape, surface charge, corona formation affect reactivity system, thus providing guide on new formulations could gain favorable efficacy/safety profile.
Язык: Английский
Процитировано
6Diabetologia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
Язык: Английский
Процитировано
0